<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054002</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269674</org_study_id>
    <secondary_id>RPCI-RP-9812</secondary_id>
    <nct_id>NCT00054002</nct_id>
  </id_info>
  <brief_title>Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma</brief_title>
  <official_title>Surgery and Intracavitary Photodynamic Therapy (PDT) for the Treatment of Malignant Pleural Mesothelioma; The Use of Light Delivery Fibers With Large Diffusers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to&#xD;
      light to kill cancer cells. Combining photodynamic therapy with surgery may be an effective&#xD;
      treatment for malignant mesothelioma.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining photodynamic therapy with&#xD;
      surgery in treating patients who have malignant mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of adjuvant photodynamic therapy with large diffuser fibers in&#xD;
           patients with malignant mesothelioma undergoing surgery.&#xD;
&#xD;
        -  Compare results of this regimen in these patients to historical controls.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive porfimer sodium IV over 5-10 minutes on day 1. Patients undergo pleurectomy&#xD;
      or pleuropneumonectomy followed by intracavitary photodynamic therapy on day 3.&#xD;
&#xD;
      Patients are followed at 1 month, every 4 months for 2 years, and then every 6 months for 3&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>1 month, every 4 months for 2 years, and then every 6 months for 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of results from this regimen to historical controls</measure>
    <time_frame>At completion of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxic effects</measure>
    <time_frame>1 month, every 4 months for 2 years, and then every 6 months for 3 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Lung surgery</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Lung surgery</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porfimer sodium</intervention_name>
    <description>iv</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant mesothelioma, including the&#xD;
             following cell types:&#xD;
&#xD;
               -  Mixed mesothelial&#xD;
&#xD;
               -  Sarcomatous&#xD;
&#xD;
          -  Stage I or II disease using the Butchart system as determined by CT scan or MRI&#xD;
&#xD;
          -  Disease confined to 1 hemithorax&#xD;
&#xD;
          -  No tumor involvement of esophagus or heart as evidenced by CT scan&#xD;
&#xD;
               -  Pericardial or diaphragmatic involvement allowed if disease is limited to the&#xD;
                  ipsilateral chest&#xD;
&#xD;
               -  N2 disease allowed if no contralateral pleural involvement&#xD;
&#xD;
          -  No adenocarcinoma or nonmesothelioma sarcoma of the chest wall&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 4,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8.5 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 3.0 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT less than 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 3.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Arterial partial pressure of carbon dioxide (pCO_2) less than 50 torr at rest&#xD;
&#xD;
          -  Predicted postoperative FEV_1 at least 800 mL with maximum oxygen consumption/kg at&#xD;
             least 15 mL/min&#xD;
&#xD;
          -  Predicted postoperative total lung capacity at least 40% of hemoglobin and alveolar&#xD;
             ventilation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No other concurrent malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No contraindication to general anesthetic&#xD;
&#xD;
          -  No history of porphyria&#xD;
&#xD;
          -  No indicated sensitivity to porfimer sodium&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the chest&#xD;
&#xD;
          -  No prior radiotherapy for mesothelioma&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd L. Demmy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Todd Demmy, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>epithelial mesothelioma</keyword>
  <keyword>sarcomatous mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

